MarginsXMarginsX
Home › Markets › PVCT

Provectus Biopharmaceuticals, Inc. (PVCT)

PVCT is quoted over the counter, not listed on an exchange. Provectus Biopharmaceuticals, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Close · November 16, 2026
$0.0459
+6.7% on the day
1-year return
-29.4%
Market cap
$19.3M
Nano cap. From the Nov 16, 2026 close × 420.3M shares (10-Q cover page, Nov 10, 2026)
P/E and P/S
Net loss over the period · No revenue line filed
On trailing twelve months to September 30, 2026 (10-Q)

Closes: Yahoo Finance daily closes, last bar 2026-11-16.

Profile

FieldValue
TickerPVCT, quoted over the counter
SEC CIK0000315545
OTC Markets tierOTCQB (price source, 2026-11-13)
SEC industry codePharmaceutical Preparations
Business addressKnoxville, TN
Incorporated inDE

Warning signs

Cash runway
0.9 months
$181K cash at September 30, 2026
Share count, 1 year
0.0%
2025-11-12 to 2026-11-10 · +0.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year after the date that the financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued."
10-Q 2026-11-10
Cash and burn$181K cash; operating cash flow -$611K a quarter.Report 2026-09-30
Shares outstanding420,279,879 (2026-11-10); 420,279,879 a year earlier; 419,522,119 three years earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Los Angeles, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$1.3M-$860K$181K$121KNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$983K-$358K$1.2M$185KNeeds four quarters10-Q 2026-08-13
Q1 2026
2026-03-31
Not filed-$1.3M-$358K$224K$3.0MNeeds four quarters10-Q 2026-05-14
Q4 2025
2025-12-31
$0-$1.2M-$870K$251K$559K$336K10-K 2026-03-26
Q3 2025
2025-09-30
$0-$1.3M-$840K$72K$129K$350K10-Q 2026-11-10
Q2 2025
2025-06-30
$57K-$1.8M-$523K$386K$54K$460K10-Q 2026-08-13
Q1 2025
2025-03-31
$279K-$1.1M-$1.1M$390K$125K$658K10-Q 2026-05-14
Q4 2024
2024-12-31
$14K-$2.4M-$912K$307K$406K$617K10-K 2026-03-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32017-03-06
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-07-01
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier